Preparation and related method for prevention and correction of diseased conditions in animals

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary. The preparation contains the following drugs: L-arginine monohydrochloride in amount 48-72 mg/l, L-lysine monohydrochloride in amount 48-72 mg/l, L-histidine monohydrochloride in amount 13.8-20.8 mg/l, L-isoleucine in amount 13.8-20.8 mg/l, L-leucine in amount 41.6-62.4 mg/l, L-methionine in amount 10.4-15.6 mg/l, L-phenylalanine in amount 17.2-25.8 mg/l, L-threonine in amount 20.8-31.2 mg/l, L-tryptophan in amount 7.9-10.3 mg/l, L-glutamine in amount 68.8-103.2 mg/l, L-valine in amount 17.2-25.8 mg/l, L-tyrosine in amount 27.7-41.5 mg/l, L-cystine monochloride in amount 17.9-26.9 mg/l, L-serine in amount 17.2-25.8 mg/l, glycine in amount 34.4-54.6 mg/l, L-alpha-alanine in amount 17.2-25.8 mg/l, L-proline in amount 25.6-38.4 mg/l, L-aspartic acid in amount 18.0-30.0 mg/l, L-oxyproline in amount 7.9-10.3 mg/l, L-glutamic acid in amount 48-72 mg/l, L-cysteine monohydrochloride in amount 0.12-0.70 mg/l, choline chloride in amount 0.4-3.0 mg/l, folic acid in amount 0.01-0.09 mg/l, calcium pantothenate in amount 0.01-0.09 mg/l, thiamine hydrochloride in amount 0.01-0.09 mg/l, nicotinic acid in amount 0.03-0.22 mg/l, pyridoxal monohydrochloride in amount 0.03-0.22 mg/l, riboflavin in amount 0.012-0.09 mg/l, nicotinamide in amount 0.03-0.22 mg/l, D-biotin in amount 0.01-0.09 mg/l, myoinositol in amount 0.06-0.45 mg/l, pyridoxine hydrochloride in amount 0.03-0.22 mg/l, calciferol in amount 0.01-0.09 mg/l, ascorbic acid in amount 0.06-0.45 mg/l, p-amino-benzoic acid in amount 0.06-0.45 mg/l, glucose in amount 800-1200 mg/l, and the following inorganic salts: sodium chloride in amount 7.2-8.8 g/l, potassium chloride in amount 360-440 mg/l, one-substituted potassium phosphate in amount 54-66 mg/l, two-substituted 12-aqueous sodium phosphate in amount 13.5-16.5 mg/l, 6-aqueous calcium chloride in amount 24.8-30.4 mg/l, 6-aqueous magnesium chloride in amount 9.9-11.6 mg/l, 7-aqueous magnesium sulphate in amount 9.0-11.0 mg/l, 9-aqueous ferrous nitrate in amount 0.65-0.79 mg/l, 3-aqueous sodium acetate in amount 7.1-8.7 mg/l. The method for prevention and correction of diseased conditions in animals consists in the injection introduction in an animal of said preparation in the form of an aqueous solution for prevention 2 times a week for a month in dosage 1.5-2.0 ml per 10 kg of body weight, for therapy in dosage 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, at synthetic and/or food poisoning intoxications - in a tenfold therapeutic dose. And, if a dose of the preparation exceeds 20 ml, it is injected in more points.

EFFECT: invention provides higher therapeutic and preventive effectiveness.

6 cl, 8 tbl

 

The invention relates to compounds and methods for the prevention and treatment of gipovitaminozov, normalize metabolism, enhance the body resistance, when the intoxication of farm and domestic animals and can be used in veterinary medicine.

In veterinary practice, animals often show symptoms of deficiency of several vitamins, which contributes to an unbalanced and inadequate feeding, digestive disorders, exposure to various stresses, as well as factors associated with high technologies of growing animals. To prevent deficiencies, you must use vitamin preparations, regulating metabolic processes, as well as amino acids that serve as building material for protein molecules. Amino acids, as not only the structural elements of proteins and other endogenous compounds are of great functional importance. It is important to take amino acids with cofactors, which are usually vitamins, minerals and other nutrients that help amino acids in the course of metabolic processes in the organism of animals. Preparations containing synthetic amino acids, fat soluble and water soluble vitamins, salts, trace elements, are widely used as veterinary drugs that affect the state about the Jena substances in the body and factors of nonspecific resistance.

Known composition of amino acids with minerals and calcium, has anticancer, antidepressant and anti-cancer activity (patent RF № 2151596, IPC A61K 31/197, publ. 26.06.2000 year). The composition contains ten natural amino acids with four trace elements and calcium.

However, this tool does not have sufficient preventive and therapeutic properties in the treatment of gipovitaminozov, normalization of metabolism, to increase the resistance of the organism, for detoxification with food poisoning and synthetic poisons.

Known means for improving the overall health of the body and stimulation of metabolic processes, contains placenta extract for injection, nukleinat sodium and as a source of vitamins and amino acids - growth medium for cell cultures 199 (RF patent No. 2203073, IPC A61K 31/00, publ. 20.10.2002,).

This agent is effective against a number of pathological conditions in animals, however, in its application, there is a danger of allergic reactions to introduce into the composition of the drug is alien to the body of the animal components of the placenta.

A well-known drug used in the treatment of diseases to improve the resistance of the organism (RF patent No. 21689900, IPC A61K 31/195, publ. 20.06.2000 year). In this drug as a medicinal product p is imeeetsja nutrient medium for cell cultures 199. The composition of the nutrient medium for cell cultures includes amino acids, vitamins, coenzymes, sources of lipids (cholesterol, tween 80) and carbohydrates (glucose, D-ribose, 2-deoxy-D-ribose, sodium acetate), and precursors of nucleic acids [1].

However, such a composition environment necessary for the growth of cells in culture in vitro, because the rate of synthesis of some amino acids in an isolated cell is insufficient to provide intensive growth, which is a feature of cell cultures. The needs of the cells in culture depend on many factors including the concentration of cells, their origin, of the concentration of substances required for growth of cells on the surface of the glass, the concentration of hydrogen ions in the environment and so on) and significantly different from those of cells in a living organism [2]. It is known that contained in the nutrient medium L-glutamine partially enters pyrrolidinecarbonyl acid during the first three months of storage, and a high content of aspartic acid in the environment can lead to brain disorders in experimental young animals [3, 4]. Thus ATP, which is part of the environment 199, is a drug with a very fast period of decay (about 30 seconds) and introduction intramuscular injection is not effective. In addition, the use of the composition of pitate Inoi environment, necessary for growth of cells in culture in vitro, significantly increases the cost of the drug when used as a drug in vivo.

The closest analogue (prototype) of a drug is a drug in the form of an aqueous solution containing L-lysine hydrochloride in the amount of 20-25 mg/ml, DL-methionine in the amount of 20-25 mg/ml glycine in the amount of 20-25 mg/ml, vitamin b8in the amount of 10-15 mg/ml, vitamin B12in the amount of 0.15-0.16 mg/ml, provitamin3in the amount of 15-20 mg/ml, vitamin H in the number 0,010-0.015 mg/ml, and ammonium citrate iron in the amount of 1.7-1.8 mg/ml in terms of ion Fe(+3), cobalt sulphate in the amount 0,095-0.100 mg/ml in terms of ion(+2), copper sulfate in the amount of 0,028-0,029 mg/ml in terms of ion Cu(+2), described in the patent of the Russian Federation No. 2343906, IPC AC 31/00, publ. 20.01.2009,

The closest analogue (prototype) method is a method of correction and prevention of pathological conditions in animals protected (patent RF № 2343906, IPC A61K 31/00, publ. 20.01.2009,). This method offers to perform the correction and prevention of pathological conditions in animals by introducing into the organism of an animal drug, including amino acid and vitamin complexes containing optional physiologically acceptable salts of Fe(3+), Co(2+), Cu(2+) injection once in 2-4 days when the total number of injections is not more than 10. The drug is administered to animals with a weight up to 3 kg in a dose of 0.1 ml, animals weighing from 3 to 5 kg dose of 0.25 ml, an animal with a mass of over 5 to 15 kg in a dose of 0.5 ml, and animals with a weight of more than 15 to 45 kg dose of 1 ml of the Drug is administered to horses, cattle and pigs at a dose of 1 ml per 45 kg body weight.

The technical result of the proposed drug and the method of its application is more effective prevention and treatment of gipovitaminozov, normalization of metabolism, to increase the resistance of the organism, for detoxification with food poisoning.

The technical result of the proposed drug and the method of its application is more effective prevention and treatment of diseases of various etiologies as a tonic for farm and domestic animals with anemia, gipovitaminozah, toxicosis of pregnancy, patients with bronchitis, pneumonia, dysbacterioses and others.

This technical result is achieved by the use of the drug for the prevention and correction of pathological conditions in animals, containing the following active ingredients: L-arginine monohydrochloride in the amount of 48 to 72 mg/l L-lysine monohydrochloride in the amount of 48 to 72 mg/l L-histidine, monohydrochloride in the amount of 13.8-20,8 mg/l of L-isoleucine in the amount of 13.8-20,8 mg/l L-leucine in the number of 41.6-of 62.4 mg/l L-methionine in the amount of 10.4-15.6 mg/l, L-phenyl who Lanin in the number 17,2-25,8 mg/l, L-threonine in the amount of 20.8 to 31.2 mg/l L-tryptophan in the amount of 7.9 and 10.3 mg/l L-glutamine in the number of 68.8-103,2 mg/l L-valine in an amount of 17.2 and 25.8 mg/l L-tyrosine in the number of 27.7-of 41.5 mg/l L-cystine of monochloride in the amount of 17.9-26.9 mg/l L-serine in the number of 17.2 and 25.8 mg/l glycine in the number of 34.4-54,6 mg/l, L-alpha-alanine the number of 17.2 and 25.8 mg/l L-Proline in the number 25,6 of 38.4 mg/l L-aspartic acid in the amount of 18.0-30.0 mg/l, L-hydroxyproline in the amount of 7.9 and 10.3 mg/l L-glutamic acid in the amount of 48 to 72 mg/l L-cysteine monohydrochloride in the amount of 0.12 to 0.70 mg/l of choline chloride in the amount of 0.4-3.0 mg/l folic acid in an amount of 0.01-0.09 mg/l, calcium Pantothenate in an amount of 0.01-0.09 mg/l of thiamine hydrochloride in an amount of 0.01-0.09 mg/l, nicotinic acid number of 0.03-0.22 mg/l pyridoxal monohydrochloride in the amount of 0.03-0.22 mg/l Riboflavin in the amount of a 0.012-0.09 mg/l nicotinamide in the amount of 0.03-0.22 mg/l D-Biotin in an amount of 0.01-0.09 mg/l, myo-Inositol in the amount of 0.06 to 0.45 mg/l, pyridoxine hydrochloride in the amount of 0.03-0.22 mg/l, calciferol in an amount of 0.01-0.09 mg/l ascorbic acid in the amount of 0.06 to 0.45 mg/l p-aminobenzoic acid in the amount of 0.06 to 0.45 mg/l, the glucose in the number of 800-1200 mg/l, and the following inorganic salts: sodium chloride in the amount of 7.2-8.8 g/l potassium chloride in the amount of 360-440 mg/l, potassium phosphate one-deputizing in the number 54-66 mg/l, sodium f is sporaticly disubstituted 12-water in the amount of 13.5 to 16.5 mg/l, calcium chloride 6-water in the amount of 24.8-of 30.4 mg/l, magnesium chloride 6-water in the amount of 9.9-11.6 mg/l, magnesium sulfate 7-water in the amount of 9.0-11.0 mg/l iron nitrate 9-water in the amount of 0.65-0,79 mg/l, sodium acetate 3-water in the amount of 7.1-8.7 mg/L.

This technical result is achieved by the fact that the method of prevention and correction of pathological conditions in animals by injecting into the body of the animal drug in aqueous solution, according to the invention, as drug use the drug under item 1 of the formula of the invention that is administered to the animals subcutaneously or intramuscularly with the preventive purpose 2 times a week for months at doses of 1.5-2.0 ml per 10 kg of body weight, with the purpose of treatment at the dose of 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, with intoxication due to poisoning synthetic and/or food poisons in ten times therapeutic dose. Moreover, if the dose exceeds 20 ml, then introduce it in several places.

Getting the specified result is achieved by designing the optimal qualitative and quantitative compositions and methods preparation of aqueous solutions of amino acids, vitamins, micro - and macroelements, glucose, normalizerbase metabolic processes in the animal body, as well as in the proposed scheme, the use of the drug. The experience is imentale installed dosage ensure its effectiveness for the prevention and treatment of pathological conditions in animals, related gipovitaminozom, to normalize metabolism and enhance the body resistance, when the intoxication of farm and domestic animals.

The technology of obtaining the drug. In 100 liters of purified water (pH from 5.0 to 7.0 pH units) dissolved inorganic salts: sodium chloride in the amount of 7.2-8.8 g/l potassium chloride in the amount of 360-440 mg/l, potassium phosphate one-deputizing in the number 54-66 mg/l, sodium phosphate disubstituted 12-water in the amount of 13.5 to 16.5 mg/l, calcium chloride 6-water in the amount of 24.8-of 30.4 mg/l, magnesium chloride 6-water in the amount of 9.9-11.6 mg/l, magnesium sulfate 7-water in the amount of 9.0-11.0 mg/l iron nitrate 9-water in the amount of 0.65-0,79 mg/l, sodium acetate 3-water in the amount of 7.1-8.7 mg/L. Dissolution of lead under stirring for at least 5-7 minutes

Then dissolved amino acids and vitamins: L-arginine monohydrochloride in the amount of 48 to 72 mg/l L-lysine monohydrochloride in the amount of 48 to 72 mg/l L-histidine, monohydrochloride in the amount of 13.8-20,8 mg/l of L-isoleucine in the amount of 13.8-20,8 mg/l L-leucine in the number of 41.6-of 62.4 mg/l L-methionine in the amount of 10.4-15.6 mg/l L-phenylalanine in the number of 17.2 and 25.8 mg/l of L-threonine in the amount of 20.8 to 31.2 mg/l, L-tryptophan in the amount of 7.9 and 10.3 mg/l L-glutamine in the number of 68.8-103,2 mg/l L-valine in an amount of 17.2 and 25.8 mg/l L-tyrosine in the number of 27.7-of 41.5 mg/l L-cyst is h monochloride in the amount of 17.9-26.9 mg/l, L-serine in the number of 17.2 and 25.8 mg/l glycine in the number of 34.4-54,6 mg/l, L-alpha-alanine in the number of 17.2 and 25.8 mg/l L-Proline in the number 25,6 of 38.4 mg/l L-aspartic acid in the amount of 18.0-30.0 mg/l, L-hydroxyproline in the amount of 7.9 and 10.3 mg/l L-glutamic acid in the amount of 48 to 72 mg/l L-cysteine monohydrochloride in the amount of 0.12 to 0.70 mg/l of choline chloride in the amount of 0.4-3.0 mg/l folic acid in an amount of 0.01-0.09 mg/l, calcium Pantothenate in an amount of 0.01-0.09 mg/l of thiamine hydrochloride in an amount of 0.01-0.09 mg/l, nicotinic acid number of 0.03-0.22 mg/l pyridoxal monohydrochloride in the amount of 0.03-0.22 mg/l Riboflavin in the amount of a 0.012-0.09 mg/l nicotinamide in the amount of 0.03-0.22 mg/l D-Biotin in an amount of 0.01-0.09 mg/l, myo-Inositol in the number 0.06 to 0.45 mg/l, pyridoxine hydrochloride in the amount of 0.03-0.22 mg/l, calciferol in an amount of 0.01-0.09 mg/l ascorbic acid in the amount of 0.06 to 0.45 mg/l p-aminobenzoic acid in the amount of 0.06 to 0.45 mg/l L-cystine before loading into the reactor dissolved in 0.1 mol/l hydrochloric acid solution.

Next dissolve glucose in the number of 800-1200 mg/l phenol red water-soluble in the amount of 18-22 mg/l and add a solution of sodium carbonate acid based 540-660 mg/L. Bring the volume of the solution up to 100 liters of purified water. Set the index of hydrogen ion concentration (pH) equal to 7.1 and 7.5, and then subjected prepared the initial solution sterilizing filter.

Examples 1 and 2 composition of the drug.

Example 1. The composition of the drug for prevention of diseases

L-arginine monohydrochloride in the number of 48 mg/l L-lysine monohydrochloride in the number of 48 mg/l L-histidine, monohydrochloride in the amount of 13.8 mg/l of L-isoleucine in the amount of 13.8 mg/l L-leucine in the number of 41.6 mg/l L-methionine in the amount of 10.4 mg/l L-phenylalanine in the number of 17.2 mg/l of L-threonine in the amount of 20.8 mg/l L-tryptophan in the amount of 7.9 mg/l L-glutamine in the number of 68.8 mg/l L-valine in an amount of 17.2 mg/l L-tyrosine in the number of 27.7 mg/l L-cystine of monochloride in the amount of 17.9 mg/l L-serine in the number of 17.2 mg/l, glycine in the number of 34.4 mg/l, L-alpha-alanine in the number of 17.2 mg/l L-Proline in the number of 25.6 mg/l L-aspartic acid in the amount of 18.0 mg/l, L-hydroxyproline in the amount of 7.9 mg/l L-glutamic acid in the number of 48 mg/l L-cysteine monohydrochloride in the amount of 0.12 mg/l of choline chloride in an amount of 0.4 mg/l folic acid in an amount of 0.01 mg/l, calcium Pantothenate in an amount of 0.01 mg/l of thiamine hydrochloride in an amount of 0.01 mg/l, nicotinic acid number of 0.03 mg/l pyridoxal monohydrochloride in the amount of 0.03 mg/l Riboflavin in the amount of 0.012 mg/l nicotinamide in the amount of 0.03 mg/l D-Biotin in an amount of 0.01 mg/l, myo-Inositol in the amount of 0.06 mg/l, pyridoxine hydrochloride in the amount of 0.03 mg/l, calciferol in an amount of 0.01 mg/l, serbinova acid in the amount of 0.06 mg/l, para-aminobenzoic acid in the amount of 0.06 mg/l, the glucose in the amount of 800 mg/l, sodium chloride in the amount of 7.2 g/l potassium chloride in the amount of 360 mg/l, potassium phosphate one-deputizing in the amount of 54 mg/l, sodium phosphate disubstituted 12-water in the amount of 13.5 mg/l, calcium chloride 6-water in the amount of 24.8 mg/l, magnesium chloride 6-water in the amount of 9.9 mg/l, magnesium sulfate 7-water in the amount of 9.0 mg/l iron nitrate 9-water in the number of 0.65 mg/l, sodium acetate 3-water in the amount of 7.1 mg/L.

Example 2. Part of the preparation for the correction of pathological conditions

L-arginine monohydrochloride in the amount of 72 mg/l L-lysine monohydrochloride in the amount of 72 mg/l L-histidine, monohydrochloride in the amount of 20.8 mg/l of L-isoleucine in the amount of 20.8 mg/l L-leucine in the number of 62.4 mg/l L-methionine in the amount of 15.6 mg/l L-phenylalanine in the number of 25.8 mg/l of L-threonine in the number of 31.2 mg/l L-tryptophan in the amount of 10.3 mg/l L-glutamine in the number 103,2 mg/l L-valine in the number of 25.8 mg/l L-tyrosine in the amount of 41.5 mg/l L-cystine of monochloride in the amount of 26.9 mg/l L-serine in the number of 25.8 mg/l glycine in the number of 54.6 mg/l, L-alpha-alanine in the number of 25.8 mg/l L-Proline in the number of 38.4 mg/l L-aspartic acid in the amount of 30.0 mg/l, L-hydroxyproline in the amount of 10.3 mg/l L-glutamic acid in the number 72 mg/l L-cysteine, monohydrochloride is the number 0,70 mg/l, choline chloride in the amount of 3.0 mg/l folic acid in the amount of 0.09 mg/l, calcium Pantothenate in the amount of 0.09 mg/l of thiamine hydrochloride in the amount of 0.09 mg/l, nicotinic acid in the amount of 0.22 mg/l pyridoxal monohydrochloride in the amount of 0.22 mg/l Riboflavin in the amount of 0.09 mg/l nicotinamide in the amount of 0.22 mg/l D-Biotin in the amount of 0.09 mg/l, myo-Inositol in the amount of 0.45 mg/l, pyridoxine hydrochloride in the amount of 0.22 mg/l, calciferol in the amount of 0.09 mg/l ascorbic acid in the amount of 0.45 mg/l p-aminobenzoic acid in the amount of 0.45 mg/l, the glucose in the amount of 1200 mg/l, sodium chloride in the amount of 8.8 g/l potassium chloride in the amount of 440 mg/l, potassium phosphate one-deputizing in the amount of 66 mg/l, sodium phosphate disubstituted 12-water in the amount of 16.5 mg/l, calcium chloride 6-water in the amount of 30.4 mg/l, magnesium chloride 6-water in the amount of 11.6 mg/l, magnesium sulfate 7-water in the amount of 11.0 mg/l iron nitrate 9-water in the amount of 0.79 mg/l, sodium acetate 3-water in the amount of 8.7 mg/L.

Example 3. The product of example 1 is administered to animals by injection subcutaneously or intramuscularly with the preventive purpose 2 times a week for months at doses of 1.5-2.0 ml per 10 kg of body weight (if dose exceeds 20 ml, the drug is injected in several places).

The preparation according to example 2 is administered to animals in the form of the of nycci intramuscularly or subcutaneously with the purpose of treatment at a dose of 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days. When intoxication (poisoning synthetic and food poisons) - ten times therapeutic dosage (if dose exceeds 20 ml, the drug is injected in several places).

Since in the present method uses a multicomponent preparation, was carried out to study its acute toxicity, allergenic action in laboratory animals, portability, sub-chronic toxicity.

Examples 4, 5, 6 confirm the absence of toxicity of the drug, confirm that the proposed drug has no effect, no adverse impacts on the physiological condition of the animal body, blood biochemical parameters and does not cause macro - and microscopic changes of the internal organs.

Also confirmed the efficiency of the proposed method to ensure normal growth and development of animals, treatment and prevention of diseases of different etiologies as a tonic for farm and domestic animals with anemia, gipovitaminozah, toxicosis of pregnancy, patients with bronchopneumonia, dysbacterioses and other (examples 7, 8, 9).

Example 4. Evaluation of acute toxicity of the proposed drug

Evaluation of acute toxicity of the preparations was carried out on white rats of both sexes mA the Soi 230-240, The drug was administered intragastrically in doses of 1.5; 2.5 and 3.5 ml (third dose maximum volume of the stomach). Control group animals were administered distilled water. The observations were carried out within 14 days. From wool cover, mucous membranes and condition of the ears deviations are not registered. If microscopii internal organs of animals hemorrhages and inflammatory processes are not detected. The mucous membrane of the esophagus, stomach and intestines had no signs of pathology. The mass ratios of the internal organs of the experimental animals was not different from control. Deaths of animals in any of the groups not registered. The obtained data indicate the absence of toxic effects of the proposed drug and can take it to the 4th class of low hazard substances (GOST 12.1.007-76), and sredneseriynoe dose to install is not possible.

Additional parameters of acute toxicity was determined after a single intramuscular (in the buttocks, hips) 56 outbred rats of both sexes weighing 220-240, Animals were divided into 6 experimental and one control groups of 8 animals each. The drug was administered based 650, 975, 1463, 2194, 3291, 4936 mg/kg respectively in groups. Control animals received the drug did not enter. Monitoring of laboratory animals in the Lee within 14 days. On the 15th day of the experiment animals decantation (after light ether anesthesia) and spent the anatomic dissection. In the dissection of animals in all experimental groups revealed no pathological changes, which allows to make a conclusion about the safety of the proposed composition. Additional tests of acute toxicity is also not possible to establish the LD50 for the investigational product, which allows it to include substances 4 class of danger according to the hygienic classification GOST 12.1.007-76.

Example 5. The study of allergic steps were carried out on Guinea pigs by cutaneous applications of the solution proposed composition with regard to body weight, rectal temperature, leukocyte count, reaction-specific agglomeration of cells (RSAL). As a result of the research showed that when applying the drug in the amount of 1.0 and 2.0 ml/kg for 18 days consider all metrics were within the physiological norm, statistically significant changes in rectal temperature, leukocyte count, and the results of RSAL between experimental and control groups were observed. Thus, the proposed drug has no effect and can be administered to animals with necessary for the prevention and treatment frequency.

Example 6. The study is arenosillo of the proposed drug. To assess the tolerability of the drug was formed 4 groups (3 experimental and 1 control) pigs on 7 goals each. Experimental groups the drug was administered intramuscularly at a rate of 2.0 to 6.0 and 10 ml per 10 kg of live weight (semi-therapeutic, three - and five-fold the dose of conventional therapeutic) for 20 days. It is established that during the experimental period, none of the doses of the drug did not have any negative effects on the body piglets on the biochemical parameters of blood of pigs of all groups, mortality was not observed neither in the control nor in the experimental groups. During the studied period the average daily gain of piglets in the experimental groups was higher than in the control group on 2,14; to 4.52 and 4.03 per cent, which indicates the safety of the drug and good bioavailability of the biologically active substances of the preparation. Carried out the slaughter of pigs at the end of the experimental period and macroscopic studies of the intestines and internal organs confirmed the absence of pathological changes in tissues and organs of animals subjected to injection of the highest dose of the drug.

A tolerance study on calves was carried out on calves black-motley breed in age from 2 to 10 days, which was formed 3 experimental and control groups of 5 calves in each group. Animals in the experimental group about what Bireli on the principle of analogues with regard to age, weight and physiological state. Experimental groups the drug was administered intramuscularly at a rate of 2.0; 6.0 and 10 ml per 10 kg of live weight (semi-therapeutic, three - and five-fold the dose of conventional therapeutic) for 20 days. As a result of researches it is established, that during the whole experimental period, none of the doses of the drug did not have any negative effects on the body calves. Neither in the control nor in the experimental groups, mortality was not observed. For the studied period the average daily gain of calves in the experimental groups was higher than in the control group by 5.53; 8,93 and 3,82%, which indicates the safety of the drug and good bioavailability of the biologically active substances of the preparation. Held on the twentieth day of the drug research morfomekhanicheskii the blood of the calves showed that the average number of erythrocytes increased by 0.13×1012/l, hemoglobin increased by 0.45 g/%, a color index decreased by 0.01. The number of leukocytes increased to 0.34×109/l, erythrocyte sedimentation rate decreased by 0.36 mm Such indicators can indicate a normalization of body functions - increased phagocytic activity, the improved respiratory activity of the functions of the blood and increase the resistance of the organism.

Thus, the 20-daily intramuscular injection of the piglets to weaning and bodies there offer the drug at doses of 2.0; 6.0 and 10 ml per 10 kg body weight does not adversely affect the physiological condition of the animal body, blood biochemical parameters and does not cause macro - and microscopic changes of the internal organs.

Example 7. Testing the effectiveness of the drug in example 1 with the preventive purpose was carried out on 54 pregnant sows, which were shared on the principle of steam-analogs in 3 groups of 18 animals each. The first group is the control and intramuscularly injected with sterile purified water. The second and third experimental groups were administered the drug at the rate of 1.5 and 2.0 ml per 10 kg of body weight 2 times a week during the month. The amount of preparation in one place does not exceed 15 ml. the Results are shown in table 1. As can be seen from table 1, in experimental groups, sows were born viable piglets more than in the control, 5.7 and 12.3%, respectively. Live weight of a pig at birth was also more than 0.03 and 0.07 kg

When this drug has had a positive impact on the subsequent growth of pigs: by the time the average weaning weight of piglets in the control group totaled 7.33 kg, whereas in the experimental groups - 8,15 and of 8.27 kg of the drug sows allowed to provide a higher safety pigs - 8.7 and 24.1%, which can be explained by the improvement of the General Phi is biologicheskogo body condition of sows. In the blood of sows increased the number of red blood cells: 3.1 to 6.2%. The hemoglobin concentration was also dose-dependently increased by 6.7 and 8.9%, respectively. The content of leukocytes significant differences between groups were observed. The total protein content was increased in the second group by 5.4%in the third - 7.6%. In serum were found to have more vitamin A: in the second group, - 28.6, and the third by 36.4%. The studies confirm the positive effect of the proposed drug sows and newborn piglets.

Piglets obtained from sows that were in the experiment were usazeny and continued to receive injections of the drug for therapeutic scheme, i.e 3,0-5,0 ml per 10 kg of body weight 2 times a day for 5 days. Observations were carried out up to 90-days-old piglets. It was noted the positive impact of the proposed drug and meat productivity of pigs. Animals of experimental groups according to the increase in live weight was superior to the control 7.4 and 9.6%. Hematological parameters of blood in patients received the drug piglets (90-day age)are presented in table 2, demonstrate a trend of improvement in hemoglobin, total protein, albumen index, the content of urea. The data obtained indicate good bioavailability and digestibility of the animal organism the proposed drug. The application of the proposed drug leads to a decrease in postnatal mortality and to increase the viability of offspring.

Example 8. To test the effectiveness of the drug according to example 2 with the preventive purpose of the calves were selected 28 goals from 1 to 1.5-month-old calves and formed 2 groups (control and experimental) 14 goals each. The first group was the control, the calves of the second experimental group was administered the drug to example 2 at the rate of 1.5 and 2.0 ml per 10 kg of body weight 2 times a week during the month. The drug has shown positive effect on live body weight and weight gain of calves. Table 3 shows that the average daily gain in live weight of calves in the experimental group (treated with intramuscular injections of the drug) exceeded the control by 5.1%. The cost of feed per unit of gain was lower in the experimental group 5.4%) than in the control. Safety in all groups by the end of the experiment was 100%. The injection of calves has also helped to boost their natural resistance, and therefore in the experimental group calves were sick much rare respiratory and gastrointestinal diseases. Were also carried out morphological and biochemical studies of blood of calves (table 4, 5). The results presented in table 4, indicate that the concentration of erythrocytes in calves in the experimental group the e at the end of the experiment was 10% more than in the control. There was a significant increase in the number of leukocytes. In the experimental group the number of hemoglobin increased by 15.3%, which demonstrates the positive effects of the drug. The biochemical tests of blood of calves (table 5) showed an increase in total protein in the serum of calves from the experimental group compared to the control by 7.9%. The content of vitamin a in the experimental group 17.7% was also greater than the control. In addition, serum was elevated level of ascorbic acid and vitamin E. these data show on a drug's effectiveness and appropriateness of its application to the calves, because after applying the proposed drug no external signs of avitaminosis, increased content of vitamins a, E, C in the serum of calves.

Thus, the tests of the proposed drug for prophylactic purposes in pigs and calves show that the proposed drug helps increase the safety and productivity of animals, improvement in clinical status due to the optimization of metabolic processes in the body related to the content of amino acids, vitamins and trace elements.

Example 9. To test the effectiveness of the drug according to example 2 with the medical purpose of the claimed method was used Leche is Sri calves patients with bronchopneumonia. When the diagnosis was considered anamnesis data, clinical studies, results hematologica and biochemical studies of blood sick calves.

For testing, we selected 20 goals 3-month sick calves, their average weight was 78 kg Group was formed on the principle analogues: 2 groups of 10 animals each. Conditions and feeding were identical. Animal experimental and control groups performed the necessary remedial measures. Additionally, the animals of the first group (control) received the drug used in agriculture: thevitamin (1 ml contains vitamin E, vitamin D 20000 ME, vitamin E - 10 mg), and the calves of the second group was administered the claimed preparation in example 2 intramuscularly into the buttocks area at 3.0-5.0 ml per 10 kg of body weight 2 times a day for 5 days. The results of the remedial measures is presented in table 6. Average daily liveweight gain in the experimental group of calves significantly greater than those in the control group in 2 times. In the experimental group had recovered 100% of calves, in contrast to the control, in which the mortality was 20%. After treatment of sick calves in both groups, changes in hematological and biochemical blood parameters (table 7, 8). The blood was re-taken after clinical recovery of patients calves. As a result of laboratory research has the, the blood of calves of the first group increased hemoglobin content, the number of erythrocytes. The number of cells decreased to physiological norms, there are no young forms of neutrophils. In the blood of calves experienced the second group was an increase in hemoglobin, the number of red blood cells. Changes in leukocyte formula similar to those in the first group. Also there have been significant changes in the biochemical indices of the blood of calves after their recovery. The recovered calves has increased the content of total protein, calcium. With changes in hematological parameters of blood of calves after treatment in the experimental group significantly better than the control group. The same picture is observed in the biochemical indices, indicating therapeutic activity of the proposed drug for pneumonia of calves.

When use of the drug for example 2 calves aged from 15 days to 10 months in treatment of enteritis, gastroenteritis in calves were observed improvement in General condition, appetite, normalized metabolic processes, accelerated healing processes in 2-3 times in comparison with calves, which the drug is not administered.

Example 10. The inventive method was used in the treatment of dogs with diseases and critical States, arose the sponding when ingested, the animal source of toxic substances, as well as food becomes toxic as a result of improper storage, in order to restore disturbed functions of the organs and the whole organism.

For testing of the drug were selected 29 of animals with clinical signs of enterocolitis as a complication of past poisoning or being intoxicated, ranging in age from 13 to 18 months and body weight from 7.4 to 13.6 kg All animals were placed in cages for 2 or 3 heads each. The animals were divided into 3 groups, based on analogues. The first group - 9 animal control; the second group and third group of 10 animals experienced. Animal 2 (with signs of enterocolitis) and 3 (food poisoning) experimental groups carried out the course of intramuscular injection of the drug according to example 2. The dose for injection to each animal of the 2nd group was determined in accordance with its weight from the calculation of 3.0 ml of the preparation per 10 kg of body weight, and for animals 3 groups based 30-50 ml per 10 kg of body weight depending on the condition of the body. The calculated amount of the drug was administered 2 times a day for 5 days. Animals of the control group is injected with a glucose solution.

Monitoring of animals confirmed a more rapid decrease intoxication effects in animals in the experimental groups, faster stopped phenomena dysfunction gastrointestinal t the act, disappeared signs of weakness and exhaustion. Morfomekhanicheskii the blood of dogs and quickly reached srednekamennogo level in experimental groups. The recovery of the body of animals in the experimental group was 2-3 days less than in the control.

Test results the proposed drug is effective for the prevention and auxiliary treatment of the following diseases: anemia, Hypo - and avitaminosis, poisoning, toxicosis of pregnancy, childbirth, infectious diseases (pneumonia, bronchitis, hepatitis and others). The use of the drug can reduce postnatal mortality, to improve the viability of offspring.

Thus, the inventive method has a positive therapeutic and prophylactic effect on the organism of animals, namely improves detoxification function, stimulates the normalization of the disturbed metabolism, increases immunity of the body.

Sources of information

1. New methods of culture of animal tissues. Edited Usmilenow. - M.: Mir. - 1976.

2. Adams R. Methods cell cultures for biotechnology. - M.: Mir, 1983. - 243 C.

3. Demina N.G., Balaguer BM, Rumyantsev NF study of the stability of glutamine in the process of its isolation from fermentation processes // Biotechnology. - 1992. No. 2. - p.63-67.

4. Infusion therapy and clinical nutrition. Edited Gnhusa. Frank the URT am main. - 1992. - 796 C.

Table 1
Productivity of sows, on average, per animal
IndicatorsGroup
1-control2-experimental3-experimental
The sows goal.181818
Born viable piglets12,2±0,812,9±0,513,7±0,9
Live weight, kg at birth1,21±0,041,24±0,011,28±0,07
in% of control-102,4105,7
Live weight, kg at weaning7,33±0,808,15±0,208,27±0,60
in% of control-111,1112,
The growth during lactation, kg/goal6,32±0,706,53±0,906,87±00,40
Average daily gain, g164,6±15,6to 178.4±17,3173,9±13,7
in% of control-108,3105,6
The number of piglets at weaning9,4±0,610,8±0,713.1 ħ 0.4
Safety,%77,083,795,6

Table 3
The productivity of calves and feed costs increase after 5 days of therapy
IndicatorsGroup
1-I control2-I experienced (the product of 2.0 ml/10 kg body weight)
Average daily gain, g621,5±28,3 653,2±34,7
Spent 1 kg gain, ked3,73,5

Table 4
Morphological parameters of blood of calves after 5 days of therapy
IndicatorsGroup
1-I control2-I experienced(the product of 2.0 ml/10 kg body weight)
Erythrocytes, mn·µl-14,7±0,15,2±0,3
Leukocytes, th·µl-17,9±0,68,2±0,2
Hemoglobin, ·µl-17,2±4,28,3±2,2

Table 5
Biochemical parameters of blood of calves after 5 days of therapy
IndicatorsGroup
1-control2-experimental
is the overall protein g/l64,10±1,5169,20±3,18
Vitamin a, µg/ml0,79±0,120,93±0,05
Vitamin C, ug%0,22±0,030,29±0,03
Vitamin E, ug%0,24±0,020,31±0,04
Calcium, mg%17,30±0,1418,00±0,15
Phosphorus, mg%7,20±0,116,80±0,12
Zinc, ug%178,0±3,9185,9±1,2

Table 6
The results of therapeutic interventions
GroupSore headsThe treatment durationRecovery goalsPalo goalsAverage daily gain, kg
1-I control1010 820,2
2-I experienced1051000,4

Table 8
Biochemical parameters of blood of calves
GroupCarotene, mg%Calcium, gPhosphorus, gRes. lyeGeneral. protein, g%
1-control0,250of 6.736,3836,45,6
0,2797,057,5033,37,2
2-experimental0,258to 6.806,1535,65,5
0,2828,30 to 7.7733,26,8

1. The drug for the prevention and correction of pathological conditions in animals, containing the following active ingredients: L-arginine monohydrochloride in the amount of 48 to 72 mg/l L-lysine monohydrochloride in the amount of 48 to 72 mg/l L-histidine, monohydrochloride in the amount of 13.8-20,8 mg/l of L-isoleucine in the amount of 13.8-20,8 mg/l L-leucine in the number of 41.6-of 62.4 mg/l L-methionine in the amount of 10.4-15.6 mg/l L-phenylalanine in the number of 17.2 and 25.8 mg/l of L-threonine in the amount of 20.8 to 31.2 mg/l L-tryptophan in the amount of 7.9 and 10.3 mg/l L-glutamine in the number of 68.8-103,2 mg/l L-valine in an amount of 17.2 and 25.8 mg/l L-tyrosine in the number of 27.7-of 41.5 mg/l L-cystine of monochloride in the amount of 17.9-26.9 mg/l L-serine in the number of 17.2 and 25.8 mg/l glycine in the number of 34.4-54,6 mg/l, L-alpha-alanine in the number 17,2 and 25.8 mg/l L-Proline in the number 25,6 of 38.4 mg/l L-aspartic acid in the amount of 18.0-30.0 mg/l, L-hydroxyproline in the amount of 7.9 and 10.3 mg/l L-glutamic acid in the amount of 48 to 72 mg/l L-cysteine monohydrochloride in the amount of 0.12 to 0.70 mg/l of choline chloride in the amount of 0.4-3.0 mg/l folic acid in an amount of 0.01-0.09 mg/l, calcium Pantothenate in an amount of 0.01-0.09 mg/l, thiamine hydrochloride in an amount of 0.01-0.09 mg/l, nicotinic acid number of 0.03-0.22 mg/l pyridoxal monohydrochloride in the amount of 0.03-0.22 mg/l Riboflavin in the amount of a 0.012-0.09 mg/l nicotinamide in the number is the firmness of 0.03-0.22 mg/l, D-Biotin in an amount of 0.01-0.09 mg/l, myo-Inositol in the amount of 0.06 -0,45 mg/l, pyridoxine hydrochloride in the amount of 0.03-0.22 mg/l, calciferol in an amount of 0.01-0.09 mg/l ascorbic acid in the amount of 0.06 to 0.45 mg/l p-aminobenzoic acid in the amount of 0.06 to 0.45 mg/l, the glucose in the number of 800-1200 mg/l, sodium chloride in the amount of 7.2-8.8 g/l potassium chloride in the amount of 360-440 mg/l, potassium phosphate one-deputizing in the number 54-66 mg/l, sodium phosphate disubstituted 12-water in the amount of 13.5 to 16.5 mg/l, calcium chloride 6-water in the amount of 24.8-of 30.4 mg/l, magnesium chloride 6-water in the amount of 9.9 -11,6 mg/l, magnesium sulfate 7-water in the amount of 9.0-11.0 mg/l iron nitrate 9-water in the amount of 0.65-0,79 mg/l, sodium acetate 3-water in the amount of 7.1-8.7 mg/L.

2. The method of prevention and correction of pathological conditions in animals by injecting into the body of the animal drug in aqueous solution, characterized in that the quality of the preparation use of the preparation according to claim 1, which is injected to the animals subcutaneously or intramuscularly.

3. The method according to claim 2, characterized in that when the dose of the drug in 20 ml of it is injected parts in several places.

4. The method according to claim 2 or 3, characterized in that the prophylactic drug according to claim 1 is administered 2 times a week for months at doses of 1.5-2.0 ml per 10 kg of body weight.

5. The way is about 2 or 3, characterized in that the purpose of treatment preparation according to claim 1 is administered at a dose of 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days.

6. The method according to claim 5, characterized in that during intoxication in connection with the poisoning of synthetic and/or food poisons the drug according to claim 1 is administered in a ten-fold therapeutic dose.



 

Same patents:

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to immunology and biotechnology. The invention discloses versions of a cytotoxically active CD3-specific binding structure. The structure comprises a first domain specifically binding to human CD3 and an Ig-derived second binding domain which is specific to molecules on the cell surface. The invention describes a coding nucleic acid, a vector for expressing the structure and an eukaryotic cell transformed by the vector. The invention discloses versions of compositions based on the structure for treating, preventing or alleviating various diseases and corresponding methods of treating the diseases. A method of obtaining the structure is disclosed.

EFFECT: use of the invention provides a structure with low immunological potency, which has cytotoxicity comparable to the initial structure, which may find further use in medicine.

60 cl, 18 dwg, 15 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of purifying plant extracts which mainly consist of noroxymorphone compounds and contain α,β-unsaturated noroxymorphone compounds as impurities, through (a) conversion of a plant extract or product of the next step in synthesis of the selected noroxymorphone compound as a result of conversion of hydroxyl groups present in the mixture to groups of formula -OR2 which can be split, in which R2 is an introduced radical of the said group which can be split, (b) said groups, if necessary, can be removed once more, after which (c) the obtained mixture is subjected to selective hydrogenation so that a saturated bond forms in the α,β-position of unsaturated noroxymorphone compounds and all the remaining groups which can be split are converted to a hydroxyl group, after which (d) a pure noroxymorphone compound is extracted; processing the purified noroxymorphone to naltrexone or naloxone or a salt of these compounds or a quaternary derivative of these compounds, which are known pharmaceutically active compounds particularly used for reducing psychological dependency and during drug abuse.

EFFECT: improved purification of compounds.

21 cl, 8 ex

FIELD: medicine.

SUBSTANCE: lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg of protein and more is used. A preparation for treating mycotic infections contains lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg and more of protein and represents a topical drug.

EFFECT: lower probability of recurrences in treating mycotic infections without normal flora suppression.

10 cl, 4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: for correction of endothelial dysfunction in experiment on rats dysfunction is modelled by preliminary sensitisation of animal with staphylococcus anatoxin in doze 0.1 ml subcutaneously. Then after 24 hours in the same place as anatoxin introduced is suspension of Staphylococcus aureus subcutaneously in dose 60 billions of microbial bodies in 1 ml. After that for following generalisation of infectious agent, daily massage of injection place is carried out. At this background introduced is macrolidal medication azithromycin intragastrically in dose 30 mg/kg/day.

EFFECT: method ensures activation of endothelial dysfunction correction.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: in order to estimate resorbtion function of peritoneum time during which animals achieve stage of surgical sleep in case of intraperitoneal introduction of ethaminal is determined.

EFFECT: method allows to estimate indirectly resoptive function of peritoneum in norm and under impact of aggressive factors.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery. Solution of dye is introduced in proper segmental vessel by direct injection method. Preliminarily, before introduction of dye solution, feeding artery is compressed for 2-3 minutes, dye solution is introduced more distally than compression place and after 1-2 minutes respective vein is compressed. Simultaneously area of supposed staining is influenced by source of constant magnet, placed outside of the organ surface.

EFFECT: method extends arsenal of means for marking intraorgan zones, segments of parenchymatous organs.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine and deals with restoration of reducing with age potential of cell growth of tissues in old laboratory animals. For this purpose medication "Transfer-factor" is introduced to laboratory animals in dose corresponding to 1 capsule a day per 50 kg of weight.

EFFECT: method ensures activation of T-lymphocyte function and restoration of potential of cell growth of salivary gland tissues in said group of animals.

FIELD: medicine.

SUBSTANCE: invention relates to chemical and pharmaceutical industry, namely to creation of medication reducing hematotoxicity of cytostatics. As such medication, polysaccharides from leaves of coltsfoot (Tussilago farfara L.) are used.

EFFECT: medication extends arsenal of preparations increasing efficiency of chemical therapy by reducing henatotoxicity of cytostatics.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to gynecology, and deals with treatment of complicated forms of inflammatory diseases of uterine appendages. For this purpose, when performing abdominal operation from two sides between round ligament of the uterus and isthmic part of fallopian tube medicinal mixtures of the following medications are introduced: at first - lidase 16 U in 1 ml of 0.25% Novocain, after that without removing the needle prednisolone 15 mg, amikacin 0.25 mg in 1 ml of 0.25% Novocain. Drainage of small pelvis with gauze-glove pad on lateral pockets to retrouterine space and bed of remote mass is carried out. In post-operational period antimicrobial drug is introduced intravenously. Limphotropically from two sides from anterior commisure of large pudental lips introduced are medicinal mixtures of medications: first - lidase 16 U in 1 ml of 0.25% Novocain, after that without removing the needle - prednisolone 15 mg, amikacin 0.25 mg in 1 ml of 0.25% Novocain, slowly during 15 minutes. Such introduction is carried out 1 time a day for 7-8 days.

EFFECT: method ensures stimulation of interstitial humoral transport and lymphatic drainage and fast normalisation of clinical and laboratory parametres with reduction of course dose of antimicrobial drugs.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of manufacturing biogenic stimulator, which includes 50% of biologically active mass from drone larvae, 49.7% of sodium chloride solution and 0.3% of preservative, consists in the following: in order to obtain preparation comb with alive healthy 18-22 days old drone brood is kept in refrigerator at temperature 3-4°C during 5-6 days, after that comb with brood is opened and drone larvae of the same size, light-gray colour are selected, after which drone larvae are crushed in sterile laboratory mill, diluted with sterile sodium chloride solution with concentration 0.9% in ratio 1:1 and autoclaved at temperature inside boiler 120°C and steam pressure in jacket 1.5 atmosphere for one hour, after that the mass is filtered through two layers of gause into sterile measure vessel, brought to initial volume with sterile solution of sodium chloride with concentration 0.9%, preservative (phenol) is added, preparation is poured into prepared sterile vessels observing rules of asepsis, vessels are hermetically closed, autoclaved at 120°C and steam pressure in jacket 1.5 atmosphere for 20 minutes.

EFFECT: method allows to reduce considerably terms of preparation manufacturing, increase its safety, increase storage terms Biogenic stimulator obtained in said way contributes to improvement of animal growth and development, increase of offspring preservation, reduction of feed cost per unit of body weight increase, increase of general and specific resistance of organism.

3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: there is offered the application of protein and/or peptide fractions containing at least 10.8 wt % of aspartate (or containing 12.0-40 wt % of aspartate per total protein fraction) for preparing a nutritional composition for plasma glucose level control and/or digestive insulin sensitivity enhancement in mammals, containing glucose (versions) and applicable nutritional compositions. It is shown that high amounts of aspartate, especially with the relative absence of glutamate equivalents promote glucose absorption in peripheral cells and improve a hepatic reaction on dietary glucose uptake. The nutritional composition contains protein, preferentially recovered from soya or milk and additionally enriched with aspartate in mass ratio of aspartate equivalents and glutamate equivalents (asp:glu) within 0.41:1 to 5:1.

EFFECT: enabled favourable effect on blood glucose levels in a patient suffering hyperglycemia and/or insulin resistance.

27 cl, 2 dwg, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: there is offered the application of protein and/or peptide fractions containing at least 10.8 wt % of aspartate (or containing 12.0-40 wt % of aspartate per total protein fraction) for preparing a nutritional composition for plasma glucose level control and/or digestive insulin sensitivity enhancement in mammals, containing glucose (versions) and applicable nutritional compositions. It is shown that high amounts of aspartate, especially with the relative absence of glutamate equivalents promote glucose absorption in peripheral cells and improve a hepatic reaction on dietary glucose uptake. The nutritional composition contains protein, preferentially recovered from soya or milk and additionally enriched with aspartate in mass ratio of aspartate equivalents and glutamate equivalents (asp:glu) within 0.41:1 to 5:1.

EFFECT: enabled favourable effect on blood glucose levels in a patient suffering hyperglycemia and/or insulin resistance.

27 cl, 2 dwg, 2 tbl, 7 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to immunology and biotechnology. The invention discloses versions of a cytotoxically active CD3-specific binding structure. The structure comprises a first domain specifically binding to human CD3 and an Ig-derived second binding domain which is specific to molecules on the cell surface. The invention describes a coding nucleic acid, a vector for expressing the structure and an eukaryotic cell transformed by the vector. The invention discloses versions of compositions based on the structure for treating, preventing or alleviating various diseases and corresponding methods of treating the diseases. A method of obtaining the structure is disclosed.

EFFECT: use of the invention provides a structure with low immunological potency, which has cytotoxicity comparable to the initial structure, which may find further use in medicine.

60 cl, 18 dwg, 15 tbl, 8 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to immunology and biotechnology. The invention discloses versions of a cytotoxically active CD3-specific binding structure. The structure comprises a first domain specifically binding to human CD3 and an Ig-derived second binding domain which is specific to molecules on the cell surface. The invention describes a coding nucleic acid, a vector for expressing the structure and an eukaryotic cell transformed by the vector. The invention discloses versions of compositions based on the structure for treating, preventing or alleviating various diseases and corresponding methods of treating the diseases. A method of obtaining the structure is disclosed.

EFFECT: use of the invention provides a structure with low immunological potency, which has cytotoxicity comparable to the initial structure, which may find further use in medicine.

60 cl, 18 dwg, 15 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention is aimed at compound in accordance with formula (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, which act as ligands for one or several melanocortin receptors, their pharmaceutically acceptable salts.

EFFECT: elaboration of method of peptide application and obtaining pharmaceutical compositions, which include said peptides.

132 cl, 4 tbl, 4 ex

Iap inhibitors // 2401840

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to novel IAP inhibitors, where compounds have general formula I , where X, Y, A, R1, R2, R3, R4, R4', R5, R5', R6, R6' have the same values as given in invention description.

EFFECT: obtaining novel IAP inhibitors, which can be used as therapeutic agents for treatment of malignant tumours.

16 cl, 78 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-(2-thiazolyl)amide of 2-(2-oxo-3-indolinylidene)hydrazine-4-oxo-4-phenyl-2-butenoic acid of formula: .

EFFECT: obtaining a compound having antibacterial and analgesic activity.

1 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: described are novel derivatives of 1,2,4-triazine-6-one of general formula (I) or their pharmaceutically acceptable acid-additive salts, or stereochemically isomeric forms, where rings A and B represent phenyl; values of other radicals are given in formula of invention.

EFFECT: development of efficient method of obtaining composition and application of novel compounds for treatment or prevention of HIV-infection.

22 cl, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds of formula I: and their pharmaceutically acceptable salts, in which R1-R4 have values, given in item 1 of invention formula. Said compounds possess inhibiting activity with respect to 11-beta-hydroxysteroid-dehydrogenase and can be applied for production of medications, intended for treatment and prevention of diabetes, especially, diabetes of II type, obesity, malnutrition and hypertension.

EFFECT: development of efficient method of obtaining formula I compounds and based on them pharmaceutical composition.

25 cl, 1 tbl, 149 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds of formula I: and their pharmaceutically acceptable salts, in which R1-R4 have values, given in item 1 of invention formula. Said compounds possess inhibiting activity with respect to 11-beta-hydroxysteroid-dehydrogenase and can be applied for production of medications, intended for treatment and prevention of diabetes, especially, diabetes of II type, obesity, malnutrition and hypertension.

EFFECT: development of efficient method of obtaining formula I compounds and based on them pharmaceutical composition.

25 cl, 1 tbl, 149 ex

FIELD: medicine.

SUBSTANCE: invention relates to medication including complex iron (III) compounds with carbohydrates, which have redox potential at pH 7 from 324 mV to - 750 mV relative to normal hydrogen electrode (NHE) and active redox substance, in which carbohydrates are selected from group consisting of dextranes, dextrines, oxidised or hydrogenised dextrines, as well as of pullulan, oligomers of said and/or hydrogenised pullulans, and in which redox substance (substances) are selected from group consisting of ascorbic acid, vitamin E, cysteine, physiologically acceptable phenols/polyphenols, selected from group consisting of quercitin, rutin, flavones, flavonoids, hydroquinones and glutathione.

EFFECT: said medication is intended for peroral introduction and is applied for treatment of states of iron deficiency without manifestation of unfavourable effects, such as formation of ulcerations in gastro-intestinal tract and oxidative stress.

19 cl, 6 tbl, 4 ex

Up!